Venous thromboembolism (VTE) continues to represent a leading cause of preventable morbidity and mortality among acutely ill medical patients [1]. Effective thromboprophylaxis remains a cornerstone of hospital-based care, guided by validated risk assessment models (RAMs) such as the Padua Prediction Score and the IMPROVE-VTE score [2–4]. These tools have evolved through decades of inpatient research, enabling clinicians to stratify risk and make rational decisions regarding anticoagulant therapy.
